Novartis Launches Lucentis Prefilled Syringe in Europe
Novartis has launched the prefilled syringe formulation of Lucentis (ranibizumab) in Germany, with other markets to follow throughout 2014. The prefilled syringe formulation has been specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician.
Novartis announced that it has launched the prefilled syringe formulation of Lucentis (ranibizumab) in Germany, with other markets to follow throughout 2014. The prefilled syringe formulation has been specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician.
Lucentis, an antibody fragment, has been approved in more than 100 countries for the treatment of wet age-related macular degeneration (wet AMD), visual impairment due to diabetic macular edema (DME) and for visual impairment due to macular edema secondary to retinal vein occlusion (RVO), including both branch- and central-RVO.
According to the Novartis, Lucentis prefilled syringe offers advantages, such as greater dose accuracy and more convenient treatment process as well as a reduction in the risk of adverse events from non-sterile conditions. The innovation reduces non-sterile preparatory steps and includes safety features, such as a non-retractable plunger. Design features, such as a smaller syringe barrel, makes greater dose accuracy possible. These features combined could potentially reduce waiting times and thereby improve the patient treatment experience.
Source: Novartis
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
